Investment Rating - The industry investment rating is "Overweight (Maintain)" [4] Core Insights - The recent results of the national centralized procurement for batches 1-8 have been released, which is expected to benefit leading companies with scale effects, particularly those integrated in raw material and formulation production [6] - The procurement process involved 5.1 million medical institutions and 1,091 domestic and foreign companies, with 4,163 products selected from 1,020 companies, indicating a high participation rate and a stable supply of selected products [6] - The procurement cycle is set to last until the end of 2028, allowing selected companies to secure a three-year national market, which is beneficial for capacity planning and cost optimization [6] Summary by Sections Industry Overview - The industry comprises 502 listed companies with a total market value of 73,023.15 billion yuan and a circulating market value of 67,026.08 billion yuan [2] Procurement Results - The procurement covers 316 commonly used drugs across 26 therapeutic areas, with a high selection rate of 93% for participating companies [6] - The average number of selected companies per product is 14, ensuring a diverse supply base and rich clinical choices [6] Competitive Landscape - The procurement reflects a shift in policy from "price reduction and expansion" to "price stability and quality assurance," favoring leading companies with compliance capabilities and scale advantages [6] - Companies like Huahai Pharmaceutical and Kelun Pharmaceutical have significant advantages in their respective fields, with high selection rates for major products [6] Future Outlook - The procurement process is expected to stabilize prices and industry expectations, moving the focus from "lowest price competition" to a comprehensive competition based on quality, capacity, compliance, and brand [6] - The new requirements for production experience and compliance are likely to accelerate the exit of smaller, weaker companies from the market [6]

Core Viewpoint - Enzyme Science is recognized for its innovative contributions to biomanufacturing, particularly in the development of chiral amines, and aims to lead advancements in synthetic biology and green manufacturing [2][3]. Group 1: Awards and Recognition - Enzyme Science's project on "Key Technology Innovation and Industrialization Demonstration of Biomanufacturing of Chiral Amines with Cyclic Structures" won the second prize of the 2024 Zhejiang Provincial Science and Technology Progress Award [2]. - The company has received multiple honors, including being recognized as a high-tech enterprise and a "little giant" in specialized and innovative sectors [3]. Group 2: Technological Innovations - The company utilizes protein crystallography and computational biology to reconstruct ancestral sequences and analyze the crystal structure of transaminases, enhancing enzyme stability, activity, and substrate universality [2]. - Enzyme Science has developed a "green biosynthesis - product precise separation - multi-category chiral amine large-scale manufacturing" technology system, achieving high-purity production of various chiral amines [2]. Group 3: Research and Development Efficiency - The establishment of the EnzyAI virtual computing platform has significantly improved R&D efficiency, allowing one person to achieve what previously required a team of five over several months [5]. - The number of new products developed annually has increased from two to over ten [5]. Group 4: Collaborations and Partnerships - Enzyme Science has formed partnerships with institutions like Shenzhen University of Technology to create a predictive and programmable intelligent biomanufacturing platform [5][7]. - The company is also collaborating with teams to explore marine extremophilic microbial enzyme resources and AI-assisted design [7]. Group 5: Commercialization and Market Reach - Enzyme Science has commercialized over 20 products across various sectors, including pharmaceutical intermediates and food additives, with expectations of doubling revenue this year [7]. - The company serves major global pharmaceutical firms such as AstraZeneca, Bayer, and Merck, contributing to significant medications for conditions like high cholesterol and diabetes [8]. Group 6: Future Plans and IPO - Enzyme Science plans to initiate an IPO in early 2026, with a Pre-IPO financing round aimed at expanding production capacity and enhancing cash flow, expecting a valuation exceeding 1.5 billion [8]. - The company aims to extend its applications beyond pharmaceuticals and food into sectors like new energy vehicles and textiles, contributing to carbon neutrality goals [8].

Core Insights - The report from Southwest Securities indicates that first-line treatment for driver gene-negative NSCLC (non-small cell lung cancer) patients primarily relies on PD(L)-1 ± chemotherapy, with projected market sizes for immune drugs in this segment reaching approximately 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 1: Market Overview - The driver gene-negative segment accounts for 31% of newly diagnosed NSCLC patients in both China and the U.S. [1] - The projected market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is estimated to be around 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 2: Next-Generation Immunotherapy - Next-generation immunotherapy options for NSCLC are advancing, including bispecific antibodies and IO+ADC (immuno-oncology plus antibody-drug conjugates) [2] - Current PD(L)-1 drugs, such as Pembrolizumab and Atezolizumab, have established their clinical position but face limitations in long-term efficacy, particularly in patients with low PD-L1 expression [2] Group 3: Bispecific Antibody Treatment - Bispecific antibodies can bind to two antigens or epitopes, balancing safety and efficacy, with the approval of Ivorisumab in 2024 expected to stimulate interest in PD-(L)1/VEGF therapies [3] - The clinical data and technological pathways for bispecific antibodies are gaining recognition, with the potential for tri-specific antibodies to become a new trend in immuno-oncology treatment [3] Group 4: IO+ADC Treatment - ADCs combine cytotoxic drugs with monoclonal antibodies targeting tumors, offering precise delivery and effective treatment with lower toxicity [3] - Clinical results for TROP2 ADC combined with K-drug show comparable ORR and PFS data to K-drug plus chemotherapy, providing new solutions for patients intolerant to chemotherapy [3]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]

Investment Rating - The report assigns a rating of "Outperform" to the company, indicating a positive outlook for its stock performance relative to the market [2][8]. Core Insights - The company reported a revenue of 1.058 billion yuan for 2025, reflecting a year-on-year growth of 21.8%, and a net profit attributable to shareholders of 237 million yuan, up 33.9% [5][8]. - In Q4 2025, the company achieved a revenue of 262 million yuan, a 21.5% increase year-on-year, and a net profit of 78 million yuan, which is a 26.4% increase [5][8]. - The company is expanding its generic drug product line while simultaneously advancing its new drug development, with a focus on cost reduction and efficiency improvements [5][8]. Financial Data and Profit Forecast - The company’s total revenue is projected to be 1.171 billion yuan in 2026, with a slight decrease to 1.110 billion yuan in 2027 [7]. - The net profit forecast for 2025 is 237 million yuan, followed by 174 million yuan in 2026 and 140 million yuan in 2027, indicating a decline in profitability in the following years [7][9]. - The company’s gross margin is expected to decrease from 83.4% in 2025 to 71.6% in 2027, reflecting potential pricing pressures from market competition [7]. Generic Drug Business - The sales of core products such as "复瑞彤" and "波开清" are steadily increasing, driving growth for the company [8]. - The company is proactively expanding its portfolio of generic drugs, with eight new drug registration approvals obtained in 2025 [8]. Innovative Drug Business - The company is advancing its pipeline of innovative drugs, with the DYX116 project progressing as expected, having completed Phase I clinical trials [8]. - The market for GLP-1 drugs in China is projected to reach 609 billion yuan by 2030, indicating significant growth potential for the company’s innovative drug offerings [8].

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2026-009 号 浙江华海药业股份有限公司 关于下属子公司获得药物临床试验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）的下 属子公司上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）及华博生物医 药技术（上海）有限公司（以下简称"华博生物"，华奥泰下属全资子公司）收到 国家药品监督管理局（以下简称"国家药监局"）核准签发的 HB0056 注射液项目 新增适应症的《药物临床试验批准通知书》，现将相关情况公告如下： 一、药物基本情况 药物名称：HB0056 注射液 适应症：特应性皮炎 剂型：注射液 2025 年 2 月，华奥泰获得国家药监局批准开展 HB0056 注射液关于哮喘适应症 的临床试验。具体内容详见公司于 2025 年 2 月 22 日刊登在中国证券报、上海证券 报、证券时报、证券日报及上海证券交易所网站（www.sse.com. ...

Core Viewpoint - Huahai Pharmaceutical's subsidiary Shanghai Huao Tai Biopharmaceutical Co., Ltd. and Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd. have received approval from the National Medical Products Administration for a new indication for the HB0056 injection project, specifically for atopic dermatitis [1] Group 1 - The HB0056 injection is intended for the treatment of atopic dermatitis and is in the form of an injection [1] - The clinical trial application for the new indication has been accepted and approved by the National Medical Products Administration [1] - The company has invested approximately RMB 91.69 million in the HB0056 project to date [1]

Investment Rating - The investment rating for the company is upgraded to "Outperform" [2][8]. Core Insights - The company reported a revenue of 1.058 billion yuan for 2025, representing a year-on-year growth of 21.8%, and a net profit of 237 million yuan, up 33.9% year-on-year. The fourth quarter of 2025 saw revenues of 262 million yuan, a 21.5% increase, and a net profit of 78 million yuan, up 26.4% year-on-year [5][8]. - The company is expanding its generic drug product line while simultaneously advancing new drug development. The fourth quarter profits exceeded expectations due to delayed large R&D expenditures and effective cost reduction measures [5][8]. - The company is actively increasing its pipeline of innovative drugs, with the DYX116 project progressing as expected. The drug has completed Phase I clinical trials and is set to enter Phase II trials in the first half of 2026 [8]. Financial Data and Profit Forecast - The total revenue forecast for 2025 is 1.058 billion yuan, with a projected growth rate of 21.8%. The net profit for 2025 is estimated at 237 million yuan, with a growth rate of 33.9% [7][11]. - The company’s projected net profits for 2025, 2026, and 2027 are 237 million yuan, 174 million yuan, and 140 million yuan respectively, reflecting a downward adjustment for 2026 and 2027 due to anticipated price reductions from centralized procurement [8][9]. - The company’s price-to-earnings (PE) ratios for 2025, 2026, and 2027 are projected at 18, 24, and 30 respectively, compared to an average PE of 38 for comparable companies [9][8].

Core Viewpoint - The diabetes medication market in China is experiencing rapid growth due to the increasing prevalence of diabetes driven by an aging population and rising obesity rates, alongside improvements in healthcare infrastructure and public awareness [1][8]. Industry Overview - Diabetes is characterized by chronic hyperglycemia due to insulin secretion and/or utilization defects, classified into Type 1, Type 2, gestational diabetes, and other specific types [2]. - Diabetes medications are categorized into eight classes, including insulin secretagogues, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, SGLT-2 inhibitors, insulin, and GLP-1 receptor agonists [2]. Market Growth - The market size for diabetes medications in China is projected to grow from 47 billion yuan in 2016 to 80.2 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.91% [1][8]. - By 2025, the market size is expected to reach approximately 85.7 billion yuan [1]. Patient Demographics - The number of diabetes patients in China is expected to increase from 118 million in 2016 to 148 million by 2024, with a CAGR of 2.87% [6][8]. - The adult diabetes prevalence rate in China is currently at 13.79%, which is significantly higher than the global average [6]. Competitive Landscape - The diabetes medication industry in China features a tiered competitive structure, with multinational companies like Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca leading the first tier due to their innovative drug development capabilities [8]. - Domestic companies such as Tonghua Dongbao, Gan & Lee Pharmaceuticals, and Huadong Medicine are emerging as strong competitors in the second tier, particularly in insulin and oral hypoglycemic agents [8]. Industry Trends - Future research and development in diabetes medications will focus on precision and individualized treatment, targeting specific mechanisms of Type 2 diabetes [12]. - The industry is expected to prioritize long-acting, multi-target drugs that modify disease progression, moving beyond mere blood sugar control [13]. - Companies will shift from being mere drug providers to comprehensive health management partners for diabetes patients, utilizing digital health technologies for continuous monitoring and personalized care [14].

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a supplementary application to produce a new specification (0.1g) of injectable cytarabine, expanding its product line and enhancing market competitiveness [1][4]. Group 1: Drug Information - The drug name is injectable cytarabine, with a new specification of 0.1g approved for domestic production [1]. - The drug is classified as a chemical drug and is used for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children, with efficacy against other types of leukemia as well [2]. - The injectable cytarabine was first developed by Upjohn and launched in the U.S. in June 1969, with domestic approval in September 1988 [2]. Group 2: Financial and Market Impact - The company has invested approximately RMB 8.17 million in the research and development of injectable cytarabine [3]. - The domestic market sales for injectable cytarabine are projected to reach approximately RMB 306 million by 2025 [2]. Group 3: Company Impact - The approval of the 0.1g specification is considered equivalent to passing a consistency evaluation, which will further enrich the company's product line and enhance its market competitiveness [4].